Abivax to reveal promising ulcerative colitis data at UEG conference

Abivax (NASDAQ:ABVX), a clinical-stage biotechnology company, reported that three significant abstracts concerning its leading drug candidate, obefazimod, will be showcased at the United European Gastroenterology (UEG) Week from October 12-15 in Vienna, Austria.

The research focuses on the treatment of moderately to severely active ulcerative colitis.

"We look forward to returning to UEGW to share new analysis of our Phase 2b trial data on obefazimod," said Chief Medical Officer Fabio Cataldi, MD.

"With this presentation, we have observed additional evidence that obefazimod has the potential to advance the treatment paradigm, designed to be a once-daily oral therapy, for people living with ulcerative colitis."

Following the announcement, Abivax's share price remained steady at $11.16 during premarket trading.